<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940114-1-00021</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The meetings will be held on Monday, January 31, 1994, and Tuesday, February 1, 1994, 9 a.m. to 4:30 p.m. Registration by January 15, 1994, is required. Interested persons, whether or not they are able to attend, may submit written comments on the skin protectant drug product aspects of the issues described in this notice by March 2, 1994, referencing the docket number found in the heading of this document. Three copies of all comments are to be submitted, except that individuals may submit one copy.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4702 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> Food and Drug Administration <!-- PJG 0012 frnewline -->  <CFRNO>21 CFR Part 347</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 78N&hyph;0021]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> Talc; Consumer Uses and Health Perspectives; Public Meetings <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice of public meetings.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) and the  <!-- PJG 0012 frnewline --> International Society of Regulatory Toxicology and Pharmacology (ISRTP) are announcing forthcoming public meetings to discuss the latest toxicologic and epidemiologic studies and how they reflect on issues related to the safe use of talc in consumer products. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The meetings will be held on Monday, January 31, 1994, and Tuesday, February 1, 1994, 9 a.m. to 4:30 p.m. Registration by January 15, 1994, is required. Interested persons, whether or not they are able to attend, may submit written comments on the skin protectant drug product aspects of the issues described in this notice by March 2, 1994, referencing the docket number found in the heading of this document. Three copies of all comments are to be submitted, except that individuals may submit one copy.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The meetings will be held at the Lister Hill Auditorium, National Institutes of Health, Bethesda, MD. Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=2 --> Regarding registration and over-the-counter (OTC) skin protectant drug products contact: William E. Gilbertson, Center for Drug Evaluation and Research (HFD&hyph;810), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;594&hyph;5000. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Regarding cosmetic products contact: John E. Bailey, Jr., Center for Food Safety and Applied Nutrition (HFS&hyph;100), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202&hyph;205&hyph;4530. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  of June 20, 1990 (55 FR 25204 at 25232), FDA proposed talc, 45 to 100 percent, as Category I (generally recognized as safe and effective and not misbranded) as an OTC skin protectant active ingredient for the treatment and prevention of diaper rash. Specific warnings and directions were proposed for powder products containing talc. The final monograph for OTC skin protectant drug products will be published in a future issue of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> . The discussion of talc at these public meetings may be considered by the agency in the preparation of this final monograph for OTC skin protectant drug products. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The purpose of these meetings is to provide a forum for an updated discussion of the origins, manufacture, characterization, toxicology, and epidemiology of talc and related products. The principal focus will be on the latest toxicologic and epidemiologic studies, particularly as they reflect on the safe uses of talc in consumer products. <!-- PJG 0012 frnewline --> The following topic areas will be discussed: (1) Characteristics of cosmetic-grade talc; (2) a history of the uses of talc in a variety of consumer products; (3) current quality control measures to insure safety; (4) the regulatory history of talc; (5) recent National Toxicology Program studies of chronic pulmonary exposure of rodents to talc and the relevance of these studies to human risk assessment; and (6) the significance of contrasting epidemiologic studies of talc exposure.  <!-- PJG 0012 frnewline --> Speakers and panelists will include well-known regulatory specialists, toxicologists, epidemiologists, pathologists, talc product manufacturers, talc production experts, and consumer representatives. A critical panel discussion by speakers and invited experts will complete each session. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: January 11, 1994 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;1083 Filed 1&hyph;12&hyph;94; 8:47 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            